comparemela.com
Home
Live Updates
Alirocumab Approved for Heterozygous Familial Hypercholester
Alirocumab Approved for Heterozygous Familial Hypercholester
Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older
Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.
Related Keywords
,
Maryp Mcgowan ,
Regeneron Pharmaceuticals Inc ,
Family Heart Foundation ,
Regeneron Pharmaceuticals ,
Centers For Disease ,
Drug Administration ,
Family Heart ,
Disease Control ,
Randomized Clinical ,